TVRD Company Profile and Key Details

TVRD has shown mixed momentum, losing -1.63% over the past week and -89.5% over the past quarter, though year-to-date performance is down -1.63%. Short-term trend indicators are bullishly aligned (SMA20 9.84%, SMA50 9.54%, SMA200 -76.96%). The stock’s 14-day RSI is 51.29 (neutral), while the ATR of 0.36 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -89.58% below its high and over 21.66% above its low. Average 10-day trading volume of 146.85 thousand shares is below the 3-month average of 332.22 thousand, indicating normal recent market interest.

Tvardi Therapeutics, Inc. generated EPS of -$9.85 over the past year. Five-year average earnings growth is 12.29%. Wall Street analysts project EPS growth of -19.88% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $78.00 to $15.00. The high target offers 1614.29% upside. The low target suggests 229.67% downside. The mean target is $53.60. This offers 1078.02% upside. Tvardi Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by -28.92%. The prior quarter beat by 96.08%. Over the last six quarters, Apple has recorded several small beats. These include 450.43% in May 13, 2025.

Tvardi Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$14.24. This means the shares are trading below this model’s fair value.

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) shares are flat -1.63% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Tvardi Therapeutics, Inc. trading at a premium to the broader market with a P/E of -3.06. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $53.60, suggesting 1078.02% upside. Our AI forecast model points to short-term weakness (-4.62% over two weeks), a medium-term rise (349.01% over three months), and a longer-term gain (843.08% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Tvardi Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.62%, with price expected at $4.34 by January 23, 2026, within a range of $4.14 to $4.54 3-Month Outlook: Projected rise of 349.01%, reaching $20.43 by April 09, 2026, with a range of $19.83 to $21.10. 1-Year Outlook: Projected gain of 843.08%, with price at $42.91 by December 31, 2026, within a range of $42.20 to $43.58.

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) closed at $4.55 USD, gaining $0.32 (7.57%) from the previous close of $4.23. The stock is currently mid-range between its 52-week high and low $3.74 and $43.65. With a market capitalization of about $42.69 million, Tvardi Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.09). Key stats such as the average daily volume over the past year has been around 337.16 thousand shares, in line with its 52-week average. Headquartered in Sugar Land, TX, Tvardi Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Imran Alibhai, the company employs approximately 17 people and listed since April 16, 2025. Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need.

Tvardi Therapeutics, Inc. trades at a P/E ratio of -3.06, slightly below the S&P 500 average, with a price-to-sales ratio of 10.61 and a price-to-book ratio of 1.53 suggesting the stock is closer to book value. The P/FCF stands at -1.35, also above market averages.